DELTICOM-AG
26.11.2015 11:47:38 CET | Business Wire | Press release
It’s buzzing on our roads and motorways. In the first nine months of 2015, there were almost 18% more trucks and commercial vehicles registered in the UK than last year.* In light of these figures, it is worth doing some forward planning and invest wisely. In the UK, the number of road traffic accidents leading to personal injury involving goods vehicles rose in 2014 by 6% in comparison to the previous year.** New tyres can make an absolutely critical contribution to safe mobility.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151126005106/en/
That’s why safety experts advise transport companies and business people who run a small fleet to service their vehicles intensively. Not only does this contribute to increased working life, it also makes an important contribution to road safety. During long, dark European winters with constantly changing weather conditions, having perfect grip increases the mobility of goods transporters and businesses by a significant multiple. “It’s worth investing in fresh tyres , not only when they’re worn, or you have to change because of the season. Very often, every millimetre counts, such as in tricky traffic situations. With new tyres , both driver and business owner are well equipped. Over the last few years, we have specialised in supplying a wide range of complete winter tyres size 17.5”, as these tyres, in particular, cover the whole spectrum of small fleet operators. Business people can count on our online car tyre shops , with excellent availability of 17.5” tyres in all price/performance categories” , says Andreas Wilmsmeier, Key-Account Manager Truck and Commercial Tyres EU at Delticom . He continues: “Our customers benefit from a wide variety of high-quality tyres. More and more transport experts are on the road in the best possible way with our own brand Goodride. Goodride truck tyres are characterised by a high level of reliability and economy”.
At the Delticom online stores for dealers and garages attractive packages are offered to all kind of businesses, no matter if small or large. With a winter discount promotion in December the online tyre dealer supports the safety of its customers. For each purchased truck tyre 10 euro discount will be granted per at the online shops for professional customers in Germany , Austria , Switzerland , France , Italy , Spain and the Netherlands (in Switzerland 10 CHF). The winter discount promotion starts at 1st of December and ends on the 31st of December 2015.
Buying tyres online provide numerous benefits: the stores are “open all hours” - 365 days a year, 24/7, thus saving that valuable resource - time. In addition, business owners can increase efficiency by benefitting from low-cost deals all year round. The truck / commercial vehicle team at Delticom can also offer personal advice if required. Within the UK, the tyres are generally dispatched in 2 - 4 days.
* Source: www.smmt.co.uk
** Source: www.gov.uk
Tyres for trucks, light trucks and commercial vehicles you can find in the online shops for:
- Dealers: www.yourtyres.co.uk , www.autoreifenonline.de , www.autoreifenonline.at , www.autoreifenonline.ch , www.pneus-auto.fr , www.pneumatici123.it , www.neumaticos123.com , www.porbanden.nl
- Fleet clients: www.fleettyres24.co.uk , www.flotten24.de , www.flotten24.at , www.flotten24.ch , www.flotte24.fr , www.flotta24.it , www.fleet24.nl
Truck tyres also available at the online shops for consumers : www.mytyres.co.uk/Truck-Tyres , www.reifendirekt.de , www.reifendirekt.at , www.reifendirekt.ch/LKW-Reifen.html , www.123pneus.fr/pneus_camion , www.gommadiretto.it/Pneumatici_autocarri , www.neumaticos-online.es/Neumaticos_camiones , www.autobandenmarkt.nl/Vrachtwagenbanden
Tyre tests: www.tyretests.com
Information about the company: www.delti.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005106/en/
Contact:
Delticom AG
Susanne Kindor-d’Unienville
T: +49 511 93634852
E-Mail:
susanne.kindor@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom